BioSpace News Archive

CytoRecovery, Inc., a leader in marker free technologies for the enrichment, sorting, and recovery of live cells, announced today that the National Science Foundation (NSF) has approved its application to receive a Phase II SBIR Research Grant.

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the presentation of additional results from its completed Phase 3 LIGHTHOUSE trial of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer, at the upcoming ASCO GU 2023 Genitourinary Cancers Symposium (ASCO GU).

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February.

Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.

The Lung Cancer Research Foundation announced that its 2023 funding mechanisms are now open for submission.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) today announced the pricing of a public offering of 3,225,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 6,450,000 shares of its common stock at an offering price to the public of $4.83 per share and associated warrant.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a clinical-stage drug development company and QuantalX Neuroscience Ltd; the developer of Delphi-MD, a clinically objective neurodiagnostic medical device, announced today a collaboration to improve early diagnosis and treatment of neurodegenerative diseases.

Attendees at this year’s American College of Foot and Ankle Surgeons Annual Scientific Conference in Los Angeles, California, will be among the first to see the UNITE Ankle Fusion Plating System.

For decades, people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) have faced multiple obstacles.

February 9, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”) today announces sales orders results for the year 2022 following a strong quarter for VINIA® in both the United States and Israel.